



## Andreas Wildi

Dr. med. et lic. iur. HSG  
Partner  
Phone +41 58 658 29 15  
andreas.wildi@walderwyss.com



Andreas Wildi, born in 1972, is a medical doctor and an attorney at law. He consults and represents Dow Jones and Nasdaq listed multinational companies as well as mid- and small cap enterprises in the Life Sciences sector. He mainly focuses on Swiss and international reimbursement & pricing law of pharmaceuticals and other therapeutic products. Regulatory issues of pharmaceuticals, medical devices, special nutrition, cosmetics, genetic testing, stem cell- and blood products are his further key areas of practise.

Andreas Wildi studied medicine at the University of Zurich and graduated as medical doctor (MD). Working part-time in hospital, GP-practice and on international rescue missions, he completed his law degree at the University of St. Gallen HSG (MLaw). Before passing the bar exam, he gained his first professional legal experience as clerk with the Cantonal Court of Schaffhausen and with a recognised business law firm in Zurich. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health. Thereafter, Andreas Wildi broadened his market access expertise internationally, as EMEA market access law director for Janssen Pharmaceuticals (Johnson & Johnson). Since 2012, he has built up his legal practise in a large, well accepted Zurich business law firm. In 2015, Walder Wyss elected Andreas Wildi as their partner.

Andreas Wildi works in German, French and English. He is admitted to all Swiss Courts and guest lecturer on pharmaceutical law at the University of Lucerne's Faculty of Law.

---

## Selected Publications

---

**Liberté de choix de la thérapie vs principe du caractère économique dans le domaine de la liste des spécialités**  
by Andreas Wildi, Daniel Staffelbach and Stephanie Eggimann  
November 2020

**Therapiewahlfreiheit vs. Wirtschaftlichkeitsgebot im Bereich der Spezialitätenliste**  
by Andreas Wildi, Daniel Staffelbach and Stephanie Eggimann  
November 2020

**Chapter 16: Switzerland**  
by Andreas Wildi [co-author], Markus R. Frick [co-author], Marija Petrovic [co-author], Benno Fischer-Siddiqui [co-author] and Monika Kawa [co-author]  
in: van Wyk/Kleyn (Ed.) (Editor[s]), "International Pharmaceutical Law and Practice"  
2018

**Chapter 16: Switzerland**  
by Andreas Wildi [co-author], Markus R. Frick [co-author], Marija Petrovic [co-author], Benno Fischer-Siddiqui [co-author] and Monika Kawa [co-author]  
in: van Wyk/Kleyn (Ed.) (Editor[s]), "International Pharmaceutical Law and Practice"  
2017

**Update: Postponement of EU Medical Device Regulation implementation due to COVID-19**  
by Andreas Wildi and Monja Sieber  
May 2020

**The Life Sciences Law Review Chapter 28 - Switzerland**  
by Andreas Wildi and Celine Weber  
in: The Life Sciences Law Review - 8th Edition, pp. 412 - 525, May 2020

**Postponement of EU Medical Device Regulation implementation due to COVID-19**  
by Andreas Wildi and Monja Sieber  
April 2020

For a complete list of publications please visit our website:  
[www.walderwyss.com/andreas.wildi](http://www.walderwyss.com/andreas.wildi)